Galmed Pharma (GLMD) Tops Q3 EPS by 19c

Galmed Pharma (NASDAQ: GLMD) reported Q3 EPS of $0.05, $0.19 better than the analyst estimate of ($0.14).

For earnings history and earnings-related data on Galmed Pharma (GLMD) click here.

You May Also Be Interested In

• SanDisk and Micron surge as Apple confirms memory price pass-through
• Stifel downgrades Intuit to Hold on growth concerns, cuts target price
• Kroger meets earnings expectations, revenue tops estimates